GlyB4 is a novel fusion protein containing a “decoy” extracellular HER4 NRG1 receptor fused to the heparin-binding domain of NRG1, which targets the decoy receptor to the same sites where NRG1 acts (Ma et al., 2009; Loeb and Song, 2019), leading to reduced microgliosis and synapse and motor neuron loss in ALS animals (Liu et al., 2018). This evidence concerns the gene NRG1 and amyotrophic lateral sclerosis.